



HOME INFUSION CHEMOTHERAPY TREATMENT FOR PATIENTS WITH MALIGNANT HAEMATOLOGICAL DISORDERS

C. ALARCON-PAYER¹, A. MARTÍN ROLDÁN¹, M.D.M. SÁNCHEZ SUÁREZ¹, <u>A. JIMÉNEZ MORALES¹</u>, J.M. PUERTA PUERTA²

¹HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES, PHARMACY SERVICE, GRANADA, GRANADA SPAIN.

²HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES, HEMATOLOGY SERVICE,, SPAIN.

Key words: Home-based chemotherapy, Hemato-oncology, Home infusion, Safe, Acceptance

Background and importance

Home-based chemotherapy is becoming a valid alternative to hospital-based treatment for patients with malignant haematological disorders.

Aim and objectives

To evaluate the benefits of implementing a home infusion chemotherapy treatment for patients with malignant haematological disorders.

Material and methods

Prospective observational February 2016 to September 2023

The hematologist selected patients with autonomy for self-care and good family support.

The chemotherapy protocols administered at home:

ESHAP
Etoposide 40mg/m² IV 2h days 1 to 4
Cytarabine 2000 mg/m² IV 2h day 5
Cisplatin 25mg/m² 22h days 1 to 4
Prednisone 60mg/m² oral days 1 to 5,

DHAOx:
Oxaliplatin 130 mg/m² IV 2h day 1
Cytarabine 2000mg/m²/12h 2h day 2
Dexamethasone 40mg oral days 1-4

EPOCH:
Etoposide 50mg/m²+
Doxorubicine 10mg/m²+
Vincristine 0,4mg/m² continuous IV
infusion 24h days 1-4,
Cyclophosphamide 750mg/m² IV day 5
Prednisone 60mg/m² oral days 1-5.

Results

43,4% with non-Hodgkin's lymphoma received ESHAP

- Second line
- median age 51 years



32,6% with mantle cell lymphoma received DHAOX

- First line
- Median age 46 years

23,9% with aggressive non-Hodgkin's lymphoma received EPOCH

- First line
- Median age 42 years

Optimization of waiting lists by 90%



Acceptance of the procedure increased in 92% of patients



Risk of infection by nosocomial microorganisms

A saving of 2500€ per patient was achieved.

95% of patients very satisfied receiving their chemotherapy treatment

Conclusion and relevance

Home Infusion Chemotherapy Treatment has been an effective, safe and feasible process. It has managed to avoid hospitalization of hemato-oncology patients receiving IV chemotherapy, saving hospital stays, reducing nosocomial infections and improving quality of life.